Chardan Capital Weighs in on Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Investment analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Tourmaline Bio in a research report issued to clients and investors on Wednesday, April 23rd. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($4.10) for the year. Chardan Capital has a "Buy" rating and a $70.00 price target on the stock. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Chardan Capital also issued estimates for Tourmaline Bio's FY2026 earnings at ($4.73) EPS.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its earnings results on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02.

A number of other research analysts have also issued reports on TRML. HC Wainwright boosted their target price on Tourmaline Bio from $49.00 to $50.00 and gave the company a "buy" rating in a report on Friday, March 14th. Lifesci Capital initiated coverage on shares of Tourmaline Bio in a research report on Monday, February 24th. They issued an "outperform" rating and a $58.00 price objective on the stock. Finally, Wedbush upped their price objective on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $49.33.

Tourmaline Bio Stock Down 8.4 %

TRML traded down $1.50 on Monday, hitting $16.35. 130,497 shares of the company traded hands, compared to its average volume of 268,396. Tourmaline Bio has a 12-month low of $11.56 and a 12-month high of $29.79. The company has a 50 day moving average of $15.15 and a 200-day moving average of $19.29. The stock has a market capitalization of $419.95 million, a PE ratio of -5.76 and a beta of 2.14.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TRML. Brooklyn Investment Group purchased a new stake in shares of Tourmaline Bio during the 4th quarter worth $32,000. Tower Research Capital LLC TRC boosted its holdings in Tourmaline Bio by 297.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock worth $33,000 after buying an additional 1,232 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Tourmaline Bio during the fourth quarter worth about $47,000. Virtus ETF Advisers LLC acquired a new position in Tourmaline Bio during the fourth quarter worth about $64,000. Finally, GAMMA Investing LLC increased its holdings in Tourmaline Bio by 4,481.7% in the first quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock valued at $114,000 after buying an additional 7,350 shares in the last quarter. Hedge funds and other institutional investors own 91.89% of the company's stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.